News

BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder

Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis...

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on New ‘Dendranib’ Nanomedicine Candidate at the 16th International Society of Neuroimmunology Congress (ISNI)

Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, in a mouse model...

Aruna Bio Announces Oral Presentation on Treatment Opportunities of Lead Program, AB126 at the Exosome Based Therapeutic Development Summit and Applications of Exosomes BioProcess International Conference & Exhibition

error: Content is protected !!